Enrolling By Invitation PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT06303583

Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma (CRIS)

Sponsor: Qiu Guoqin

Conditions Esophageal Squamous Cell Carcinoma

Interventions carboplatin paclitaxel radiotherapy tislelizumab

Updated 3 times since 2024 Last updated: Mar 4, 2024 Started: Jun 1, 2022 Primary completion: Aug 31, 2024 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Esophageal Squamous Cell Carcinoma, this trial is ongoing. The trial is conducted by Qiu Guoqin and has accumulated 3 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Enrolling By Invitation PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Enrolling By Invitation PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Apr 2024 — Jul 2024 [monthly]

Enrolling By Invitation PHASE1_PHASE2

First recorded

Jun 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Qiu Guoqin

Data source: Zhejiang Cancer Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China